Clear Street Expands Healthcare Equity Research Focus
Clear Street, a well-known cloud-native financial technology firm, is thrilled to announce the expansion of its equity research offerings into the healthcare sector, particularly focusing on biotechnology. This new initiative aims to modernize the brokerage ecosystem while providing heightened insights for their growing client base, which includes asset managers, institutions, and professional traders.
The Healthcare Research Initiative
The healthcare research franchise at Clear Street complements the company’s existing prime brokerage and clearing solutions. This expanded service will not only offer institutional clients essential tools and resources but will also allow them to navigate complex market landscapes more effectively.
Ed Tilly, the President and CEO-Elect of Clear Street, commented on the launch, stating, "The initiative solidifies our commitment to adapt to our clients' evolving demands. We believe that adding healthcare equity research will enhance our existing suite of products, providing a more comprehensive experience for institutional clients as they execute their investment strategies globally."
Leadership in Healthcare Equity Research
At the helm of the new Healthcare Research framework is Director of Research, Mara Goldstein. She leads a team dedicated to delivering insightful market analyses and investment perspectives to the firm’s expanding base of institutional clients. Recognizing the rapid growth and significant importance of biotechnology, Goldstein stated, "With the ever-increasing number of biotechnology firms, our goal is to spotlight under-followed companies that our clients, including specialized hedge funds, should be aware of."
Meet the Key Analysts
To initiate this comprehensive coverage, Clear Street has appointed Kaveri Pohlman, Ph.D. and William "Bill" Maughan, Ph.D. as Managing Directors and Senior Equity Analysts under the guidance of Mara Goldstein. Dr. Pohlman’s expertise primarily targets oncology and autoimmune diseases, enriching the firm's ability to provide detailed insights into the healthcare landscape.
Before joining Clear Street, Dr. Pohlman served as a Senior Analyst at BTIG, where she focused on both large and small-cap biotech firms. Her educational background is impressive, with a Ph.D. in molecular and cellular biology from SUNY Downstate Medical Center, as well as credentials in both biotechnology and business from respected institutions.
Dr. Bill Maughan supports the team with extensive knowledge in various therapeutic areas, including oncology and genetic medicine. Previously, he was a Senior Biotechnology Analyst for Canaccord Genuity. His academic credentials, including a Ph.D. in Biochemistry from Weill Cornell Graduate School, further contribute to the robust research focus at Clear Street.
Launch Coverage in Biotechnology
Clear Street's healthcare research will kick off by examining several notable biotechnology companies, including:
Healthcare: Biotechnology
- Cargo Therapeutics (Nasdaq: CRGX)
- Century Therapeutics (Nasdaq: IPSC)
- Cullinan Therapeutics (Nasdaq: CGEM)
- Delcath Systems (Nasdaq: DCTH)
- Enliven Therapeutics (Nasdaq: ELVN)
- Erasca (Nasdaq: ERAS)
- Immatics (Nasdaq: IMTX)
- Janux Therapeutics (Nasdaq: JANX)
- MoonLake Immunotherapeutics (Nasdaq: MLTX)
- Nuvation Bio (NYSE: NUVB)
- Protagonist Therapeutics (Nasdaq: PTGX)
- YmAbs Therapeutics (Nasdaq: YMAB)
Conclusion
The launch of the Healthcare Equity Research marks a significant enhancement to Clear Street’s growing research capabilities and its commitment to supporting institutional clients seeking specialized insights into the healthcare sector. Additionally, with the recent establishment of Clear Street UK, the firm continues to lay the groundwork for a comprehensive, global institutional business driven by cutting-edge technology.
About Clear Street
Clear Street is committed to modernizing the brokerage landscape by leveraging financial technology and innovative services. The firm provides its clients with real-time data along with superior products, tools, and teams designed to navigate global capital markets effectively. Their goal is to create an all-in-one platform that serves every asset class, in any country, and in any currency.
Frequently Asked Questions
What is Clear Street's new initiative for healthcare research?
Clear Street has expanded its equity research offerings to include healthcare, focusing particularly on the biotechnology sector.
Who are the key analysts leading the Healthcare Equity Research?
The healthcare research initiative is led by Mara Goldstein, with Kaveri Pohlman and Bill Maughan as Managing Directors and Senior Equity Analysts.
What companies are included in Clear Street's launch coverage?
Launch coverage includes biotech firms such as Cargo Therapeutics (Nasdaq: CRGX), Century Therapeutics (Nasdaq: IPSC), and MoonLake Immunotherapeutics (Nasdaq: MLTX).
How does this expansion affect Clear Street's clients?
This expansion enhances Clear Street's offerings, providing institutional clients with valuable insights to navigate the biotechnology market effectively.
What is Clear Street's overall mission?
Clear Street aims to modernize the brokerage ecosystem using technology to help market participants succeed in their investments while minimizing risk.
